217 related articles for article (PubMed ID: 35078243)
1. ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
El Jabbour T; Misyura M; Cowzer D; Zimmermann M; Rimkunas V; Marra A; Derakhshan F; Selenica P; Parilla M; Setton JS; Ceyhan-Birsoy O; Kemel Y; Catchings A; Ranganathan M; Ku GY; Janjigian YY; Zinda M; Koehler M; Stadler Z; Shia J; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2022 May; 114(5):761-770. PubMed ID: 35078243
[TBL] [Abstract][Full Text] [Related]
2. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
van Duin M; van Marion R; Vissers KJ; Hop WC; Dinjens WN; Tilanus HW; Siersema PD; van Dekken H
Cytogenet Genome Res; 2007; 118(2-4):130-7. PubMed ID: 18000363
[TBL] [Abstract][Full Text] [Related]
3. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
van Dekken H; Tilanus HW; Hop WC; Dinjens WN; Wink JC; Vissers KJ; van Marion R
Cancer Genet Cytogenet; 2009 Feb; 189(1):37-42. PubMed ID: 19167610
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
5. Gastroesophageal junction and gastroesophageal junction carcinoma : a short update.
Ekmektzoglou KA; Apostolopoulos P; Samelis G; Alexandrakis G
Acta Gastroenterol Belg; 2016; 79(4):471-479. PubMed ID: 28209106
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.
Li Z; Zou X; Xie L; Dong H; Chen Y; Liu Q; Wu X; Zhou D; Tan D; Zhang H
PLoS One; 2013; 8(11):e80665. PubMed ID: 24236193
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
9. SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach.
Neil AJ; Zhao L; Isidro RA; Srivastava A; Cleary JM; Dong F
Mod Pathol; 2023 Jun; 36(6):100183. PubMed ID: 37054973
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.
Bornschein J; Wernisch L; Secrier M; Miremadi A; Perner J; MacRae S; O'Donovan M; Newton R; Menon S; Bower L; Eldridge MD; Devonshire G; Cheah C; Turkington R; Hardwick RH; Selgrad M; Venerito M; Malfertheiner P; ; Fitzgerald RC
Int J Cancer; 2019 Dec; 145(12):3389-3401. PubMed ID: 31050820
[TBL] [Abstract][Full Text] [Related]
11.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.
van Dekken H; Geelen E; Dinjens WN; Wijnhoven BP; Tilanus HW; Tanke HJ; Rosenberg C
Cancer Res; 1999 Feb; 59(3):748-52. PubMed ID: 9973227
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract][Full Text] [Related]
14. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.
Wood AC; Zhang Y; Mo Q; Cen L; Fontaine J; Hoffe SE; Frakes J; Dineen SP; Pimiento JM; Walko CM; Mehta R
Oncologist; 2022 Apr; 27(4):307-313. PubMed ID: 35380714
[TBL] [Abstract][Full Text] [Related]
16. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
[TBL] [Abstract][Full Text] [Related]
17. Comparative histochemical evaluation of mucins expression in fetal esophagus and adenocarcinomas of the gastroesophageal junction.
Vernygorodskyi S; Rekun T; Zhuchenko P
Exp Oncol; 2018 Oct; 40(3):223-227. PubMed ID: 30285012
[TBL] [Abstract][Full Text] [Related]
18. A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal
Adeshuko FA; Squires MH; Poultsides G; Pawlik TM; Weber SM; Schmidt C; Votanopoulos K; Fields RC; Maithel SK; Cardona K
Am Surg; 2017 Jan; 83(1):82-89. PubMed ID: 28234131
[TBL] [Abstract][Full Text] [Related]
19. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.
Bashash M; Shah A; Hislop G; Treml M; Bretherick K; Janoo-Gilani R; Leach S; Le N; Bajdik C; Brooks-Wilson A
PLoS One; 2013; 8(3):e59157. PubMed ID: 23527119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
